High-grade osteosarcoma of the extremities;Trattamento dell'osteosarcoma delle estremità ad alto grado di malignità

Minerva Ortopedica e Traumatologica

Volumn 53, Issue 4, 2002, Pages 195-203

  Fagioli, F ^a,b   Palmero, A ^a   Berger, M ^a   Gastaldo, L ^a   Pessolano, R ^a   Berta, M ^a   Del Prever, A Brach ^a   Madon, E ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b SANT ANNA HOSPITAL   (Italy)

Author keywords

Chemotherapy; Hematopoietic stem cell transplantation; Neoplasm metastasis; Osteosarcoma, therapy

Indexed keywords

CISPLATIN; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE;

BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER LOCALIZATION; DOSE RESPONSE; DRUG MEGADOSE; HUMAN; OSTEOSARCOMA; PREOPERATIVE TREATMENT; PROGNOSIS; REVIEW; SURVIVAL RATE;

EID: 18344407943     PISSN: 00264911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Bacci G, Picci P, Ruggieri P, Mercuri M, Avella M, Capanna R et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer 1990;65:2539-53.
2. Bacci G, Picci P, Ferrari S, Ruggieri P, Casadei R, Tienghi A et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of Methotrexate followed by Cisplatin and Doxorubicin. Cancer 1993;72:3227-38.
3. Meyers PA, Gorlik R, Heller G, Casper E, Lane, J, Huvos AG et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) Protocol. J Clin Oncol 1998;16:2452-8.
4. Saeter G, Alvegard TA, Elomaa I, Stenwig A, Holmstrom T. Solheim P. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single agent high-dose methotrexate. A Scandinavian Sarcoma Group study. J Clin Oncol 1991;9:1766-75.
5. Bacci G, Picci P, Avella M, Ferrari S, Casadei R, Ruggieri P et al. Effect of intra-arterial versus intravenous cisplatin in addition to systemic adriamycin and high-dose methotrexate on histologic tumor response of osteosarcoma of the estremities. J Chemother 1992;4:189-95.
6. Lewis IJ, Weeden S, Machin D, Stark D, Craft A. Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. J Clin Oncol 2000;18:4028-37.
7. Saeter G. Treatment of osteosarcoma with high-dose methotrexate-containing neoadjuvant chemotherapy. Scandinavian Sarcoma Group data. Med Pediatr Oncol 1996;27:263.
8. Saeter G, Wiebe T, Wiklund T, Monge O, Wahlqvist Y, Engstrom K et al. Chemotherapy in osteosarcoma. The Scandinavian Sarcoma Group experience. Acta Orthop Scand 1999;70(Suppl. 285):74-82.
9. Bacci G, Briccoli A, Ferrari S, Saeter G, Donati D, Longhi A et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide. Oncol Rep 2000;7:339-46.
10. Smith MA, Ungerleider RS, Horowitz ME, Simon R. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 1991;83:1460-70.
11. Bacci G, Picci P, Avella M, Dallari D, Ferrari S, Prasad R et al. The importance of dose-intensity in neoadjuvant chemotherapy of osteosarcoma: a retrospective analysis of high-dose methotrexate, cisplatinum and adriamycin used preoperatively. J Chemother 1990;2:127-35.
12. Bacci G, Ferrari S, Delepine N, Bertoni F, Picci P, Mercuri M et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively, treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol 1998;16:658-63.
13. Picci P, Sangiorgi L, Rougraff BT, Neff JR, Casadei R, Campanacci M. Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 1994;12:2699-705.
14. Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987;5:21-6.
15. Campanacci M, Bacci G, Bertoni F, Picci P, Minutillo A, Franceschi C. The treatment of osteosarcoma of the extremities: twenty year's experience at the Istituto Ortopedico Rizzoli. Cancer 1981;48:569-81.
16. Bacci G, Gherlinzoni F, Picci P, Van Horn JR, Jaffe N, Guerra A et al. Adriamycin-methotrexate high dose versus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: a randomized study. Eur J Cancer Clin Oncol 1986;22:1337-45.
17. Rosen G, Marcove RC, Huvos AG, Caparros BI, Lane JM, Nirenberg A et al. Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol 1983;106(Suppl.):55-67.
18. Bacci G, Lari S. Current treatment of high grade osteosarcoma of the extremity: review. J Chemother 2001;13:235-43.
19. Rosen G, Marcove RC, Caparros B, Nirenherg A, Kosloff C, Huvos AG. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 1979;43:2163-77.
20. Bacci G, Ferrari S, Longhi A, Perin S, Forni C, Fabbri N et al. Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy. Eur J Cancer 2001;37:32-8.
21. Provisor AJ, Ettinger LJ, Nachmaan JB, Krailo MD, Makley JT, Yunis EJ et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 1997;15:76-84.
22. Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfurst C et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988;6:329-37.
23. Rosen G, Capparos B, Huvos AG, Kosloff C, Nirenbrg A, Cacavio A et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982;49:1221-30.
24. Bramwell VH. The role of chemotherapy in the management of non-metastatic operable extremity osteosarcoma. Semin Oncol 1997;24:561-71.
25. Bacci G, Ferrari S, Tienghi A, Bertoni F, Mercuri M, Longhi A et al. A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity. Eur J Surg Oncol 2001;27:98-104.
26. Hudson M, Jaffe MR, Jaffe N, Ayala A, Raymond AK, Carrasco H et al. Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience. J Clin Oncol 1990;8:1988-97.
27. Jaffe N, Smith D, Jaffe MR, Hudson M, Carrasco H, Wallace S et al. Intraarterial cisplatin in the management of stage IIB osteosarcoma in the pediatric and adolescent age group. Clin Orthop 1991;270:15-21.
28. Ferrari S, Bacci G, Picci P, Mercuri M, Briccoli A, Pinto D et al. Long term follow-up and postrelapse survival in patients with nonmetastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann Oncol 1997;8:765-71.
29. Bacci G, Picci P, Ferrari S, Avella M, Brach del Prever A, Ruggieri P et al. Neoadjuvant chemotherapy for nonmetastatic osteosarcoma of the extremities: the recent experience at the Rizzoli Institute. Cancer Treat Res 1993;62:299-308.
30. Bacci G, Ferrari S, Mercuri M, Longhi A, Capannna R, Tienghi A et al. Neoadjuvant chemotherapy for extremity osteosarcoma. Preliminary results of the Rizzoli's 4th study. Acta Oncol 1998;37:41-8.
31. Bacci G, Briccoli A, Ferrari S, Longhi A, Mercuri M, Capanna R et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer 2001;37:2030-9.
32. Grem JL, King SA, Wittes RE, Leyland-Jones B. The role of methotrexate in osteosarcoma. J Natl Cancer Inst 1988:80:626-55.
33. Rosen G. An opinion supporting the role of high-dose methotrexate in the treatment of osteosarcoma. Cancer Treat Res 1993;62:49-54.
34. Marti C, Kroner T, Remagen W, Berchtold W, Cserhati M, Varini M. High-dose ifosfamide in advanced osteosarcoma. Cancer Treat Rep 1985;69:115-7.
35. Harris MB, Cantor AB, Goorin AM, Shochat SJ, Ayala AG, Ferguson WS et al. Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. Med Pediatr Oncol 1995;24:87-92.
36. Saeter G, Hoie J, Stenwig AE, Johansson AK, Hannisdal E, Solheim P. Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer 1995;75:1084-93.
37. Meyers PA, Heller G, Healey JH, Huvos A, Applewhite A, Sun M et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 1993;11:449-53.
38. Miniero R, Brach del Prever A, Vassalto E, Nesi F, Busca A, Fagioli F et al. Feasibility of high-dose chemotherapy and autologous peripheral blood stem cell transplantation in children with high grade osteosarcoma. Bone Marrow Transplant 1998;22(Suppl. 5):S37-S40.
39. Saeter G, Talle K, Solheim O. Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide. Cancer Chemother Pharmacol 1995;36:172-5
40. Saeter G, Alvegard TA, Monge OR, Strander H, Turesson I, Klepp R et al. Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group Phase II Study. Eur J Cancer 1997;33:1551-8.
41. Saleh RA, Graham-Pole J, Cassano W, Abbot F, Vander Griend R, Dickson N et al. Response of osteogenic sarcoma to the combination of etoposide and cyclophosphamide as neoadjuvant chemotherapy. Cancer 1990;65:861-5.
42. Meyer WH, Pratt CB, Rao BN, Luo X, Jenkins JJ, Shearer P et al. Curative therapy for osteosarcoma without cisplatin. Preliminary experience with SJCRH OS-91. Med Pediatr Oncol 1996;27:226.
43. Petrilli AS, Kechichian R, Broniscer A, Garcia RJ, Tanaka C, Francisco J et al. Activity of intraarterial carboplatin as a single agent in the treatment of newly diagnosed extremity osteosarcoma. Med Pediatr Oncol 1999;33:71-5.
44. Robson H, Meyer S, Shalet SM, Anderson E, Eden OB. Comparative evaluation of cisplatin and carboplatin sensitivity in osteosarcoma cell lines. Med Pediatr Oncol 1999;33:167.
45. Meyer WH, Pratt CB, Poquette CA, Bhaskar NR, Parham D, Marina N et al. Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St. Jude Children's Research Hospital OS-91 trial. J Clin Oncol 2001;19:171-85.
46. Valabrega G, Fagioli F, Corso S, Madon E, Brach del Prever A, Biasin E et al. ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells. Br J Cancer, in press.
47. Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am 1997;44:973-89.
48. Michelagnoli MP, Lewis IJ, Gattamaneni HR, Bailey CC, Lashford LS. Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma. Br J Cancer 1999;79:1174-8.
49. Ward WG, Mikaelian K, Dorey F, Mirra JM, Sassoon A, Holmes EC et al. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol 1994;12:1849-58.
50. Meyer WH, Schell MJ, Kumar APM, Rao BN, Green AA, Champion J et al. Thoracotomy for pulmonary metastatic osteosarcoma: an analysis of prognostic indicators of survival. Cancer 1987;59:374-9.
51. Cassano W, Graham-Pole J, Dickinson N. Etoposide, cyclophosphamide, cisplatin and doxorubicin as neoadjuvant chemotherapy for osteosarcoma. Cancer 1991;68:1899-902
52. Pratt CB, Epelman S, Jaffe N. Bleomycin, cyclophosphamide and dactinomycin in metastatic osteosarcoma: lack of tumor regression in previously treated patients. Cancer Treat Rep 1987;71:421-3.
53. Chan KW, Petropoulos D, Choroszy M, Herzog C, Jaffe N, Ater J et al. High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric solid tumors. Bone Marrow Transplant 1997;20:1039-43.
54. Lucidarme N, Valteau-Couanet D, Oberlin O, Couanet D, Kalifa C, Beaujean F et al. Phase II study of high-dose thiotepa and hematopoietic stem cell transplantation in children with solid tumors. Bone Marrow Transplant 1998;22:535-40.
55. Sauerbrey A, Bielack S, Kempf-Bielack B, Zoubek A, Paulussen M, Zintl F. High-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (ASCT) as salvage therapy for relapsed osteosarcoma. Bone Marrow Transplant 2001;27:933-7.
56. Colombat PH, Biron P, Coze C, Rosti G, Siimes MA, Blay JY et al. Failure of high-dose alkylating agents in osteosarcoma. Bone Marrow Transplant 1994;14:665-6.
57. Saylors RL, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001;19:343-9.
58. Fagioli F, Aglietta M, Tienghi A, Ferrari S, Brach del Prever A, Vassallo E et al. High dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian Sarcoma Group study. J Clin Oncol 2002;20;2150-6.
59. Slavin S. New strategies for bone marrow transplantation. Curr Opin Immunol 2000;12:542-51.
60. Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000;111:18-29.
61. Or R, Ackerstein A, Nagler A, Kapelushnik J, Naparstek E, Samuel S et al. Allogeneic cell-mediated immunotherapy for breast cancer after autologous stem cell transplantation: a clinical pilot study. Cytokines Cell Mol Ther 1998;4:1-6.
62. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000;343:750-8.
63. Childs R, Drachenberg D. Allogeneic stem cell transplantation for renal cell carcinoma. Curr Opin Urol 2001;11:495-502.
64. Storb RF, Champlin R, Riddell SR, Murata M, Bryant S, Warren EH. Non-myeloablative transplants for matignant disease. Hematology 2001:375-91.
65. Corradini P, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 2002;99:75-82.
66. Toren A, Nagler A, Rozenfeld-Granot G, Levanon M, Davidson J, Bielorai B et al. Amplification of immunological functions by subcutaneous injection of intermediate-high dose interteukin-2 for 2 years after autologous stem cell transplantation in children with stage IV neuroblastoma. Transplantation 2000;70:1100-4.
67. Sluga M, Windhager R, Lang S, Heinzl H, Bielack S, Kotz R. Local and systemic control after ablative and limb sparing surgery in patients with osteosarcoma. Clin Orthop 1999;358:120-7.
68. Glasser DB, Lane JM, Stage IIB osteogenic sarcoma. Clin Orthop 1991;270:29-39.
69. Bacci G, Ferrari S, Mercuri M, Bertoni F, Picci P, Manfrini M et al. Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy. Acta Orthop Scand 1998;69:230-6.
70. Picci P, Sangiorgi L, Bahamonde L, Aluigi P, Bibiloni J, Zavatta M et al. Risk factors for local recurrences after limb-salvage surgery for high-grade osteosarcoma of the extremities. Ann Oncol 1997;8:899-903.
71. Rougraff BT, Simon MA, Kneist JS, Greenberg DB, Mankin HJ. Limb salvage compared with amputation for osteosarcoma of the distal end of the femur. A long-term oncological, functional, and quality-of-life study. J Bone Joint Surg Am 1994;76:649-56.
72. Bielack SS, Kempf-Bielack B, Winkler K. Osteosarcoma: relationship of response to preoperative chemotherapy and type of surgery to local recurrence. J Clin Oncol 1996;14:683-4.
73. Kempf-Bielack B, Bielack S, Bieling P, Delling G, Fuchs N, Heise U et al. Local Failure (LF) of osteosarcoma (OS): risk factors and prognosis. Results of the cooperative OS study group COSS. ASCO Proceedings 1996;15:520.
74. Spanier SS, Shuster JJ, Vander Griend RA. The effect of local extent of the tumor on prognosis in osteosarcoma. J Bone Joint Surg Am 1990;72:643-53.
75. Wuisman P, Enneking WF. Prognosis for patients who have osteosarcoma with skip metastasis. J Bone Joint Surg Am 1990;72:60-8.
76. Ogihara Y, Sudo A, Fujinami S, Sato K, Miura T. Current management, local management, and survival statistics of high-grade osteosarcoma. Experience in Japan. Clin Orthop 1991;270:72-8.
77. Babin SR, Simon P, Babin-Boilletot A, Bellocq JP. Can amputation be avoided in local recurrence after limb salvage for high grade osteosarcoma? A case report and a review of the literature. Int Orthop 1995;19:374-6.
78. Fidias P, Demetri G, Harmon DC. Navelbine shows activity in previously treated sarcoma patients: phase II results from MGH/DANA Farber/partner's cancercare study. Proc Am Soc Clin Oncol 1998;17:1977.
79. Epelman S, Aguiar S, Silvia A, Metaragno R, Nogueira M, Grande MT et al. Phase II study of Vinoretbine (VNR) in children and adolescents with refractory or recurrent cancer. Med Pediatr Oncol 1997;29:338.
80. Epelman S, Aguiar S, Melaragno R, Rossi CG, Silvia AM, Andrea ML et al. High response rate of Vinorelbine (VNR) in children and adolescents with refractory or recurrent rhabdomiosarcomas (RMS) or other sarcomas (STS). Med Pediatr Oncol 1999;33:227.
81. Delaloge S, Yovine A, Taamma A, Riofrio M, Brain E, Raymond E et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients - preliminary evidence of activity. J Clin Oncol 2001;19:1248-55.
82. Casanova M, Casali PG, Sessa C, Bacci G, Aglietta M, Riccardi R et al. Ecteinascidin-743 in infusione di tre ore in pazienti affetti da sarcoma pretrattato in progressione o alla recidiva: studio di fase II. Riv Ital Pediatr 2002;1(Suppl. 2):150.
83. Bergeron S. A review of the past, present, and future clinical trials from the Children's Cancer Group. J Pediatr Oncol Nurs 1998;15:98-102.
84. Cosetti M, Wexler LH, Calleja E, Trippett T, LaQuaglia M, Huvos AG et al. Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience. J Pediatr Hematol Oncol 2002;24:101-5.
85. Pollak MN, Polychronakos C, Richard M. Insulinlike growth factor I: a potent mitogen for human osteogenic sarcoma. J Natl Cancer Inst 1990;21;82:301-5.
86. Pollak M, Sem AW, Richard M, Tetenes E, Bell R. Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. J Natl Cancer Inst 1992;84:966-71.
87. Baldini N, Scotlandi K, Barbanti-Brodano G, Manara MC, Maurici D, Bacci G et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 1995;333:1380-5.
88. Brach del Prever A, Massara FM, Besenzon L, Bianchi M, Picci P, Briccoli A et al. Trattamento dell'osteosarcoma metastatico con verapamile, ciclosporina e chemioterapia. Descrizione di un caso clinico. Minerva Pediatr 1995;47:147-51.